-- Surgery 2 Question Bank: Topic 55 - Surgical Oncology Principles (33 MCQs)
-- Category: Surgery 2 (a0000002-0000-0000-0000-000000000002)
-- Topic: Surgical Oncology Principles (c0000055-0000-0000-0000-000000000055)

INSERT INTO questions (topic_id, category_id, question_text, option_a, option_b, option_c, option_d, option_e, correct_option, explanation, difficulty, cognitive_level) VALUES
('c0000055-0000-0000-0000-000000000055'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'The TNM staging system evaluates:', 'Only tumour size', 'Tumour size, Nodal involvement, and Metastasis', 'Only lymph nodes', 'Only metastasis', 'Treatment response', 'B', 'TNM staging: T = primary tumour size/extent, N = regional lymph node involvement, M = distant metastasis. Used for most solid tumours. Provides prognostic information and guides treatment.', 'easy', 'knowledge'),

('c0000055-0000-0000-0000-000000000055'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'The goal of curative surgery in cancer is:', 'Debulking only', 'Complete resection with negative margins (R0 resection)', 'Palliative relief', 'Sampling only', 'Biopsy', 'B', 'Curative intent: R0 resection (microscopically negative margins). R1 = microscopic residual, R2 = macroscopic residual. Margin status is key prognostic factor in most solid tumours.', 'easy', 'knowledge'),

('c0000055-0000-0000-0000-000000000055'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Neoadjuvant therapy refers to:', 'Treatment after surgery', 'Treatment given before definitive surgery', 'Palliative treatment', 'Hormone therapy', 'Radiation alone', 'B', 'Neoadjuvant therapy: chemotherapy/radiotherapy before surgery. Goals: downstage tumour, improve resectability, treat micrometastases early. Used in rectal, breast, esophageal cancer, etc.', 'easy', 'knowledge'),

('c0000055-0000-0000-0000-000000000055'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Adjuvant therapy is given:', 'Before surgery', 'After surgery to eliminate residual disease', 'Instead of surgery', 'For palliation only', 'Never in cancer', 'B', 'Adjuvant therapy: after surgery to eliminate microscopic residual disease, reduce recurrence. Based on pathological staging, high-risk features. Examples: chemotherapy in colon cancer, radiation in breast cancer.', 'easy', 'knowledge'),

('c0000055-0000-0000-0000-000000000055'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'The sentinel lymph node is:', 'Most distant node', 'First node draining the tumour site', 'Largest node', 'Any positive node', 'Central node', 'B', 'Sentinel node: first lymph node receiving drainage from primary tumour. Identified using dye/radiotracer. If negative, further nodal dissection may be avoided. Used in breast cancer, melanoma.', 'easy', 'knowledge'),

('c0000055-0000-0000-0000-000000000055'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Sentinel lymph node biopsy is standard in which cancers?', 'Colon cancer', 'Breast cancer and melanoma', 'Lung cancer', 'Pancreatic cancer', 'Gastric cancer', 'B', 'SLNB standard: breast cancer (clinically node-negative) and melanoma (intermediate thickness). Reduces morbidity of complete lymphadenectomy if sentinel node negative. Accuracy >95%.', 'easy', 'knowledge'),

('c0000055-0000-0000-0000-000000000055'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Palliative surgery in cancer aims to:', 'Cure the cancer', 'Relieve symptoms and improve quality of life', 'Achieve R0 resection', 'Replace chemotherapy', 'Diagnose cancer', 'B', 'Palliative surgery: symptom control when cure not possible. Examples: bypass for obstruction, stoma for bowel obstruction, bleeding control. Decisions based on prognosis, performance status, patient wishes.', 'easy', 'application'),

('c0000055-0000-0000-0000-000000000055'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Tumour markers are useful for:', 'Screening general population', 'Monitoring treatment response and detecting recurrence', 'Diagnosis in all cases', 'Staging always', 'Replacing biopsy', 'B', 'Tumour markers: best for monitoring (response, recurrence) rather than screening/diagnosis. Examples: CEA (colorectal), CA 19-9 (pancreatic), AFP/HCG (germ cell), PSA (prostate).', 'medium', 'knowledge'),

('c0000055-0000-0000-0000-000000000055'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Carcinoma in situ is characterized by:', 'Distant metastasis', 'Malignant cells confined within epithelium without invasion', 'Lymph node involvement', 'Vascular invasion', 'Stromal invasion', 'B', 'Carcinoma in situ: malignant cells confined to epithelium, basement membrane intact, no stromal invasion. High-grade dysplasia. Curable with complete excision. No metastatic potential (no access to lymphatics/vessels).', 'medium', 'knowledge'),

('c0000055-0000-0000-0000-000000000055'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'The purpose of frozen section during surgery is:', 'Better diagnosis', 'Rapid intraoperative pathological assessment for surgical decision-making', 'Permanent diagnosis', 'Research only', 'Cost saving', 'B', 'Frozen section: rapid processing (10-20 min) for intraoperative decisions. Uses: margin assessment, lymph node status, nature of lesion. Less accurate than permanent sections. Guides extent of resection.', 'medium', 'knowledge'),

('c0000055-0000-0000-0000-000000000055'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Multidisciplinary team (MDT) meetings in cancer care:', 'Are optional', 'Are essential for optimal treatment planning', 'Only for rare cancers', 'Replace patient consent', 'Delay treatment', 'B', 'MDT essential: surgeon, oncologist, radiologist, pathologist, specialist nurses discuss each case. Ensures appropriate staging, treatment plan, clinical trial consideration. Standard of care.', 'easy', 'knowledge'),

('c0000055-0000-0000-0000-000000000055'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Performance status (ECOG/Karnofsky) is important because it:', 'Is only for research', 'Predicts treatment tolerance and prognosis', 'Determines cancer stage', 'Is unrelated to treatment', 'Measures tumour size', 'B', 'Performance status: measures functional capacity. Predicts treatment tolerance, prognosis, surgical risk. ECOG 0 (fully active) to 4 (bedridden). Guides treatment intensity decisions.', 'medium', 'knowledge'),

('c0000055-0000-0000-0000-000000000055'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Lymphovascular invasion (LVI) in a tumour indicates:', 'Better prognosis', 'Higher risk of metastasis and worse prognosis', 'No clinical significance', 'Need for less treatment', 'Earlier stage', 'B', 'LVI: tumour cells in lymphatic or blood vessels. Adverse prognostic factor. Indicates higher risk of nodal/distant metastasis. May influence adjuvant treatment decisions.', 'medium', 'knowledge'),

('c0000055-0000-0000-0000-000000000055'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Tumour differentiation (grade) refers to:', 'Tumour size', 'How much tumour resembles normal tissue (well, moderate, poor)', 'Lymph node status', 'Depth of invasion', 'Patient age', 'B', 'Tumour grade: degree of differentiation. Well-differentiated (low grade) = resembles normal tissue, better prognosis. Poorly differentiated (high grade) = aggressive, worse prognosis. Independent prognostic factor.', 'easy', 'knowledge'),

('c0000055-0000-0000-0000-000000000055'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'The concept of "no-touch" technique in cancer surgery involves:', 'Gentle handling only', 'Early ligation of vascular pedicle before tumour manipulation', 'Not touching patient', 'Robotic surgery only', 'No instruments', 'B', 'No-touch technique: minimize tumour handling to prevent tumour cell dissemination. Early vascular control (vein before artery), avoid squeezing tumour. Theoretical benefit for reducing metastasis.', 'medium', 'knowledge'),

('c0000055-0000-0000-0000-000000000055'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Port site metastasis after laparoscopic cancer surgery:', 'Never occurs', 'Can occur and may relate to technique and tumour biology', 'Is more common than open surgery', 'Contraindicates laparoscopy', 'Is always fatal', 'B', 'Port site metastasis: occurs in ~1% of laparoscopic cancer surgery. Relates to tumour shedding, instrument contamination, CO2 effects. Proper technique (specimen bags, port site closure) minimizes risk.', 'medium', 'knowledge'),

('c0000055-0000-0000-0000-000000000055'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Cytoreductive surgery (debulking) is particularly useful in:', 'Breast cancer', 'Ovarian cancer', 'Colon cancer', 'Melanoma', 'Lung cancer', 'B', 'Cytoreductive surgery: maximal removal of tumour burden. Most established for ovarian cancer (plus HIPEC in peritoneal carcinomatosis). Complete cytoreduction improves survival with chemotherapy.', 'medium', 'knowledge'),

('c0000055-0000-0000-0000-000000000055'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'HIPEC (Hyperthermic Intraperitoneal Chemotherapy) is used for:', 'Brain tumours', 'Peritoneal surface malignancies', 'Lung metastases', 'Bone tumours', 'Skin cancers', 'B', 'HIPEC: heated chemotherapy delivered intraperitoneally after cytoreductive surgery. Used for peritoneal carcinomatosis (colorectal, ovarian, appendiceal, mesothelioma). Specialist centres only.', 'medium', 'knowledge'),

('c0000055-0000-0000-0000-000000000055'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Resection of liver metastases for cure is most established for:', 'Gastric cancer', 'Colorectal cancer', 'Pancreatic cancer', 'Melanoma', 'Lung cancer', 'B', 'Liver metastasectomy: best outcomes in colorectal cancer. Selection: resectable, adequate liver remnant, controlled primary, good performance status. 5-year survival 40-50% in selected patients.', 'medium', 'knowledge'),

('c0000055-0000-0000-0000-000000000055'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Pulmonary metastasectomy may be considered if:', 'Multiple bilateral metastases', 'Limited number, slow growing, controlled primary, and adequate pulmonary reserve', 'Rapid progression', 'Primary not controlled', 'Multiple organ metastases', 'B', 'Pulmonary metastasectomy: considered for colorectal, sarcoma, renal cell, germ cell tumours. Selection: controlled primary, limited resectable disease, good pulmonary function, no extrathoracic disease.', 'medium', 'application'),

('c0000055-0000-0000-0000-000000000055'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'En bloc resection in cancer surgery means:', 'Separate removal of structures', 'Removal of tumour with surrounding involved structures as single specimen', 'Minimal surgery', 'Only tumour removal', 'Piecemeal resection', 'B', 'En bloc resection: removal of tumour with adjacent involved structures as single unit without violating tumour capsule. Prevents tumour spillage, ensures clear margins. Standard for locally advanced tumours.', 'easy', 'knowledge'),

('c0000055-0000-0000-0000-000000000055'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'A positive circumferential resection margin (CRM) in rectal cancer:', 'Has no significance', 'Is associated with high local recurrence rate', 'Improves survival', 'Is expected', 'Is only found in early cancer', 'B', 'CRM in rectal cancer: positive margin (<1mm) associated with high local recurrence (>30% vs <5-10%). Key quality indicator. Total mesorectal excision technique and neoadjuvant therapy reduce positive CRM.', 'medium', 'knowledge'),

('c0000055-0000-0000-0000-000000000055'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'The main principle of oncoplastic breast surgery is:', 'Mastectomy for all', 'Combining oncological resection with plastic surgery techniques for good outcomes', 'Avoiding radiation', 'No reconstruction', 'Only for large tumours', 'B', 'Oncoplastic surgery: integrates tumour resection with plastic surgery techniques. Allows wider margins while maintaining or improving cosmesis. Volume displacement, volume replacement techniques.', 'medium', 'knowledge'),

('c0000055-0000-0000-0000-000000000055'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Risk-reducing surgery in BRCA mutation carriers may include:', 'No surgery indicated', 'Bilateral mastectomy and salpingo-oophorectomy', 'Hysterectomy only', 'Chemoprevention only', 'Surveillance only', 'B', 'BRCA carriers: risk-reducing bilateral mastectomy (reduces breast cancer risk 90-95%), bilateral salpingo-oophorectomy (reduces ovarian cancer). Offered after counselling and discussion of alternatives.', 'medium', 'application'),

('c0000055-0000-0000-0000-000000000055'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Emergency surgery in cancer patients may be needed for:', 'Staging purposes', 'Obstruction, perforation, bleeding, or sepsis', 'Primary prevention', 'Screening', 'Adjuvant therapy', 'B', 'Emergency cancer surgery: obstruction (GI, urinary), perforation, life-threatening bleeding, sepsis. May compromise oncological principles but lifesaving. May be followed by definitive cancer treatment.', 'easy', 'application'),

('c0000055-0000-0000-0000-000000000055'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Cancer cachexia is characterized by:', 'Weight gain', 'Progressive weight loss, muscle wasting, and anorexia resistant to nutritional support', 'Fluid retention', 'Obesity', 'Increased appetite', 'B', 'Cancer cachexia: multifactorial syndrome - weight loss, muscle wasting, anorexia, metabolic dysfunction. Not fully reversible with nutrition. Associated with poor prognosis, reduced treatment tolerance.', 'easy', 'knowledge'),

('c0000055-0000-0000-0000-000000000055'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Perioperative nutritional support in malnourished cancer patients:', 'Is unnecessary', 'Improves surgical outcomes and should be provided preoperatively if possible', 'Delays surgery', 'Increases complications', 'Is contraindicated', 'B', 'Nutrition in cancer surgery: malnourished patients benefit from 7-14 days preoperative nutritional support. Reduces complications, improves wound healing. Enteral preferred over parenteral.', 'medium', 'application'),

('c0000055-0000-0000-0000-000000000055'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Enhanced Recovery After Surgery (ERAS) in cancer patients:', 'Is contraindicated', 'Reduces complications and length of stay without compromising oncological outcomes', 'Increases recurrence', 'Is only for minor surgery', 'Delays chemotherapy', 'B', 'ERAS in cancer: multimodal perioperative care. Reduces morbidity, LOS, costs. Does not compromise oncological outcomes or delay adjuvant therapy. Includes early feeding, mobilization, minimal opioids.', 'medium', 'knowledge'),

('c0000055-0000-0000-0000-000000000055'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Immunotherapy in cancer works by:', 'Directly killing cancer cells', 'Enhancing the immune systems ability to recognize and attack cancer', 'Blocking hormones', 'Cutting off blood supply', 'Radiating tumour', 'B', 'Immunotherapy: harnesses immune system against cancer. Checkpoint inhibitors (PD-1, CTLA-4), CAR-T cells, cancer vaccines. Revolutionary advances in melanoma, lung cancer, others.', 'medium', 'knowledge'),

('c0000055-0000-0000-0000-000000000055'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Targeted therapy differs from conventional chemotherapy in that:', 'It has no side effects', 'It specifically targets molecular abnormalities in cancer cells', 'It is not effective', 'It replaces surgery', 'It only works in elderly', 'B', 'Targeted therapy: drugs targeting specific molecular alterations (HER2, EGFR, BRAF, etc.). More specific than conventional chemo. Examples: trastuzumab (HER2), imatinib (BCR-ABL), vemurafenib (BRAF).', 'medium', 'knowledge'),

('c0000055-0000-0000-0000-000000000055'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Genetic testing in cancer patients is useful for:', 'All cancers equally', 'Identifying hereditary syndromes and guiding targeted therapy', 'Screening general population', 'Determining tumour grade', 'Staging only', 'B', 'Genetic testing in cancer: germline (hereditary syndromes - BRCA, Lynch) for risk assessment and family screening. Somatic (tumour testing) for targeted therapy selection. Increasing importance in precision oncology.', 'medium', 'knowledge');
